Assessment of Paroxetine Molecular Interactions with Selected Monoamine and γ-Aminobutyric Acid Transporters.
antidepressant
monoamine and GABA neurotransmitters
monoamine transporters (MAT)
neurogenesis
paroxetine (PRX)
γ-Aminobutyric acid transporter (GAT)
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
11 Jun 2021
11 Jun 2021
Historique:
received:
04
05
2021
revised:
31
05
2021
accepted:
10
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
15
7
2021
Statut:
epublish
Résumé
Thus far, many hypotheses have been proposed explaining the cause of depression. Among the most popular of these are: monoamine, neurogenesis, neurobiology, inflammation and stress hypotheses. Many studies have proven that neurogenesis in the brains of adult mammals occurs throughout life. The generation of new neurons persists throughout adulthood in the mammalian brain due to the proliferation and differentiation of adult neural stem cells. For this reason, the search for drugs acting in this mechanism seems to be a priority for modern pharmacotherapy. Paroxetine is one of the most commonly used antidepressants. However, the exact mechanism of its action is not fully understood. The fact that the therapeutic effect after the administration of paroxetine occurs after a few weeks, even if the levels of monoamine are rapidly increased (within a few minutes), allows us to assume a neurogenic mechanism of action. Due to the confirmed dependence of depression on serotonin, norepinephrine, dopamine and γ-aminobutyric acid levels, studies have been undertaken into paroxetine interactions with these primary neurotransmitters using in silico and in vitro methods. We confirmed that paroxetine interacts most strongly with monoamine transporters and shows some interaction with γ-aminobutyric acid transporters. However, studies of the potency inhibitors and binding affinity values indicate that the neurogenic mechanism of paroxetine's action may be determined mainly by its interactions with serotonin transporters.
Identifiants
pubmed: 34208199
pii: ijms22126293
doi: 10.3390/ijms22126293
pmc: PMC8230779
pii:
doi:
Substances chimiques
GABA Plasma Membrane Transport Proteins
0
Neurotransmitter Agents
0
Vesicular Monoamine Transport Proteins
0
Paroxetine
41VRH5220H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12761-6
pubmed: 17652169
Nature. 2015 May 21;521(7552):322-7
pubmed: 25970245
Pharmacol Rev. 2011 Sep;63(3):585-640
pubmed: 21752877
Cell Tissue Res. 2018 Jan;371(1):33-46
pubmed: 28948349
Neurochem Res. 2014 Oct;39(10):1988-96
pubmed: 24852577
Neurochem Res. 2017 Jul;42(7):2019-2023
pubmed: 28190226
Acta Chem Scand B. 1975;29(8):871-6
pubmed: 1202890
J Med Chem. 2004 Jun 17;47(13):3388-98
pubmed: 15189035
Nat Commun. 2021 Apr 13;12(1):2199
pubmed: 33850134
Biochem Pharmacol. 2017 Oct 1;141:86-99
pubmed: 28800956
J Neurosci. 2007 Apr 4;27(14):3845-54
pubmed: 17409249
Protein Eng Des Sel. 2006 Mar;19(3):129-33
pubmed: 16423846
J Clin Psychiatry. 1997 Dec;58(12):520-1
pubmed: 9448653
Neuropharmacology. 2019 Dec 15;161:107411
pubmed: 30391505
Neuropharmacology. 2013 Apr;67:304-17
pubmed: 23085335
Pharmacol Rep. 2016 Apr;68(2):443-50
pubmed: 26922551
Pharmacol Ther. 2020 Jun;210:107515
pubmed: 32109488
Sci Rep. 2016 Apr 01;6:23789
pubmed: 27032980
Mol Psychiatry. 2002;7 Suppl 1:S23-8
pubmed: 11986992
Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58
pubmed: 9537821
J Chem Inf Model. 2012 Jul 23;52(7):1757-68
pubmed: 22587354
J Nucl Med. 2017 Sep;58(Suppl 2):39S-53S
pubmed: 28864611
Eur J Pharmacol. 2019 May 15;851:99-121
pubmed: 30776369
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Nat Neurosci. 2008 Jul;11(7):780-9
pubmed: 18568020
Biophys Rev. 2017 Apr;9(2):91-102
pubmed: 28510083
Mol Psychiatry. 2000 Jul;5(4):357-62
pubmed: 10889545
Nat Struct Mol Biol. 2015 Jun;22(6):506-508
pubmed: 25961798
Cell Death Discov. 2019 Mar 22;5:80
pubmed: 30911414
Int Clin Psychopharmacol. 1999 May;14 Suppl 1:S3-7
pubmed: 10468322
J Mol Model. 2009 Oct;15(10):1155-64
pubmed: 19238460
Neurochem Res. 2012 Nov;37(11):2496-512
pubmed: 22717696
Neuropharmacology. 2019 Dec 15;161:107644
pubmed: 31108110
Neuropsychiatr Dis Treat. 2011;7(Suppl 1):9-13
pubmed: 21750623
ChemMedChem. 2010 Jul 5;5(7):986-1000
pubmed: 20491137
Front Physiol. 2014 Apr 24;5:159
pubmed: 24795654
Cell Tissue Res. 2019 Jul;377(1):95-106
pubmed: 31165247
Adv Neurobiol. 2017;16:137-167
pubmed: 28828609
Trends Neurosci. 2019 Mar;42(3):164-178
pubmed: 30686490
EMBO J. 1986 Apr;5(4):823-6
pubmed: 3709526
Nat Med. 2016 Mar;22(3):238-49
pubmed: 26937618
Avicenna J Med Biotechnol. 2016 Oct-Dec;8(4):152-158
pubmed: 27920882
PLoS One. 2018 Jul 2;13(7):e0200085
pubmed: 29965988
ACS Chem Neurosci. 2020 Oct 21;11(20):3214-3232
pubmed: 32991141
Front Cell Neurosci. 2014 Jun 17;8:161
pubmed: 24987330
Comput Struct Biotechnol J. 2018 Dec 15;17:61-69
pubmed: 30619541
ACS Chem Neurosci. 2013 Feb 20;4(2):295-309
pubmed: 23421681
Asian J Psychiatr. 2017 Jun;27:101-111
pubmed: 28558878
Nature. 2016 Apr 21;532(7599):334-9
pubmed: 27049939
Assay Drug Dev Technol. 2019 Aug;17(6):285-291
pubmed: 31532713
Nucleic Acids Res. 2003 Jan 1;31(1):365-70
pubmed: 12520024
CNS Drugs. 2003;17(8):539-62
pubmed: 12775192
Neuropharmacology. 2012 Jan;62(1):42-53
pubmed: 21889518
J Biol Chem. 1994 Jun 10;269(23):15985-8
pubmed: 8206893
Neuropsychopharmacology. 2008 Dec;33(13):3201-12
pubmed: 18418363
Cold Spring Harb Perspect Biol. 2015 Sep 01;7(9):a018812
pubmed: 26330519
J Med Chem. 2005 Sep 22;48(19):6023-34
pubmed: 16162005
Sci Rep. 2015 Oct 27;5:15650
pubmed: 26503701
ACS Chem Neurosci. 2019 Jan 16;10(1):337-347
pubmed: 30222312
Biol Psychiatry. 2004 Nov 15;56(10):803-9
pubmed: 15556126
Mol Psychiatry. 2003 Aug;8(8):721-37, 715
pubmed: 12888801
J Affect Disord. 1990 Sep;20(1):1-5
pubmed: 2174069
J Neurosci. 2005 May 18;25(20):4930-40
pubmed: 15901774
Int J Mol Sci. 2021 Feb 07;22(4):
pubmed: 33562229
J Chem Inf Model. 2020 Aug 24;60(8):3958-3968
pubmed: 32649824
Depress Anxiety. 2007;24(7):495-517
pubmed: 17117412
Mol Psychiatry. 2020 Jun;25(6):1215-1228
pubmed: 30837688
CNS Drug Rev. 2001 Spring;7(1):25-47
pubmed: 11420571
Adv Neurobiol. 2017;16:283-296
pubmed: 28828616
Eur J Pharm Sci. 2017 Jan 1;96:362-372
pubmed: 27721044
Int J Mol Sci. 2020 Oct 30;21(21):
pubmed: 33143033
Comb Chem High Throughput Screen. 2009 Mar;12(3):241-9
pubmed: 19275529
Cell. 2008 Feb 22;132(4):645-60
pubmed: 18295581
Br J Pharmacol. 2006 Jan;147 Suppl 1:S82-8
pubmed: 16402124
Pharmacol Rev. 2013 Dec 31;66(1):334-95
pubmed: 24381236
Elife. 2020 Jul 03;9:
pubmed: 32618269
Brain Behav Immun. 2018 Mar;69:603-617
pubmed: 29051086
ACS Chem Neurosci. 2016 Nov 16;7(11):1607-1613
pubmed: 27596073
Biosens Bioelectron. 2018 Apr 15;102:540-552
pubmed: 29220802
Expert Opin Pharmacother. 2006 Oct;7(14):1977-87
pubmed: 17020423
Neuropsychopharmacology. 1999 Aug;21(2 Suppl):2S-8S
pubmed: 10432482
Curr Drug Metab. 2020;21(7):548-561
pubmed: 32651960